Opus Genetics is trading 5.4% down today at $3.60 amid broader biotech sector rotation and profit-taking.
- The decline extends a multi-day slide from above $4 in early July, following a period of strength driven by the company's inherited retinal disease gene therapy pipeline.
- No new company-specific news has emerged; the stock appears to be moving in tandem with broader biotech benchmarks like the XBI as investors rotate out of high-beta names.